Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin α5– and Integrin β3–Dependent Mechanism

Inhibitors of the mammalian target of rapamycin (mTOR) have improved the treatment of renal cell carcinoma (RCC). However, chronic drug exposure may trigger resistance, limiting the utility of these agents. The metastatic behavior of RCC cells, susceptible (RCCpar) or resistant (RCCres) to the mTOR...

Full description

Bibliographic Details
Main Authors: Eva Juengel, Jasmina Makarević, Michael Reiter, Jens Mani, Igor Tsaur, Georg Bartsch, Axel Haferkamp, Roman A. Blaheta
Format: Article
Language:English
Published: Elsevier 2014-04-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S147655861400030X